Bio-inspired chimeric drug delivery nano systems (Chi-DDnSs): Their fractal hologram and regulatory aspects

Abstract

Pharmaceutical Nanotechnology can provide challenges for producing innovative drugs based on bio-inspired nanostructures (advanced Drug Delivery nano Systems— aDDnSs) [1]. These systems could be correlated to the living organisms due to their self-assembly properties, their hierarchical structural organization, as well as to their biocompatibility and biodegradability characteristics. aDDnSs can be considered as new therapeutic outcomes in nanomedicine that may be able to deliver pharmacomolecules to specific tissues and can improve their PK/PD (pharmacokinetics/pharmacodynamics) behavior and affect their total bioavailability. Drug delivery is a scientific sector that promotes the innovation by designing formulation approaches that can produce aDDnSs. Drug nanocarriers produced by the combination of bionanomaterials, such as liposomes, (co)polymers and dendrimers, are considered as new classes of complex self-assembled soft nanostructures. The major advantage of such bio-inspired delivery systems lies in the ability to control the size, the structure, and the morphology of the nanoassembly, due to the cooperativity of the components. The morphology of nanoparticles has been recently described via fractal analysis [2-7]. The fractal dimension could be a useful tool for the development and characterization of innovative nanocarriers for pharmacomolecules with complete knowledge of their structural characteristics. This approach can disclose the pharmacokinetic reality of behavior of the candidate drugs, and can improve their therapeutic value by highlighting the interdependence of particle morphology and biological and pharmacokinetic processes. In conclusion, there is growing effort to refine methodologies for preparation and physicochemical characterization, in order for these new technologies to have the potential to meet regulatory requirements.